Evidence map›Paper›PMID 30450160›Full record

ArticleOncotarget2018

Knock-in of the

Colleen E Annesley, Cara Rabik, Amy S Duffield, Rachel E Rau, Daniel Magoon, Li Li, Vicki Huff, Donald Small, David M Loeb, Patrick Brown

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Murine Models of Acute Myeloid Leukemia.Frontiers in oncology · 2022
    Review
  2. Review
  3. Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome.International journal of molecular sciences · 2021
    Review
  4. RNA-Binding Proteins in Acute Leukemias.International journal of molecular sciences · 2020
    Review
  5. Review
  6. Murine Models of Acute Myeloid Leukaemia.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Colleen E AnnesleyDepartment of Pediatrics, University of Washington, Seattle, WA, USA.
Cara RabikThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Amy S DuffieldThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Rachel E RauDepartment of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Daniel MagoonThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Li LiThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Vicki HuffDepartment of Molecular Genetics/Cancer Genetics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Donald SmallThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
David M LoebCurrent affiliation: Departments of Pediatrics and Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY, USA.
Patrick BrownThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins Medicine · USSidney Kimmel Comprehensive Cancer Center · USAlbert Einstein College of Medicine · USBaylor College of Medicine · USJohns Hopkins University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Washington · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
FLT3 Tyrosine Kinase Inhibitors As Therapy for LeukemiaR01CA090668 · NCI · JOHNS HOPKINS UNIVERSITY · PI SMALL, DONALD · 2002 to 2018
$5.0M
NCI NIH HHS P30 CA006973NCI NIH HHS R01 CA090668
6 · The paper itself

Abstract

Wilms tumor 1 (WT1) is a zinc finger transcriptional regulator, and has been implicated as both a tumor suppressor and oncogene in various malignancies. Mutations in the DNA-binding domain of the

Indexed as

AMLFLT3myelodysplastic syndromeWilms tumor 1WT1

Identifiers

PMID30450160
PMCPMC6219680
OpenAlexW2897789437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.